Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment

Journal of Gynecologic Oncology

Volumn 21, Issue 4, 2010, Pages 255-261

  Yoon, Joohee ^a   Kim, Eung Sam ^b   Lee, Sung Jong ^a   Park, Chang Wook ^b   Cha, Hyung Jin ^b   Hong, Bee Hak ^b   Choi, Kwan Yong ^b  

^a The Catholic University of Korea   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Apoptosis; Cisplatin; Dendron modified DNA microarray; Ovarian cancer cell lines

Indexed keywords

CASPASE 3,APOPTOSIS RELATED CYSTEINE PROTEASE; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CISPLATIN; DEFENDER AGAINST CELL DEATH 1; EPITHELIAL MEMBRANE PROTEIN 3; FAST KINASE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHOTRANSFERASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN BINDING PROTEIN 6; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL DEATH; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; IC 50; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; OVARY CANCER; UPREGULATION; VALIDATION PROCESS;

EID: 79952409033     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.4.255     Document Type: Article

References (32)

1. Helm CW, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res 2009; 2: 2.
2. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 Suppl 4: 9-17. (Pubitemid 30344987)
3. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43. (Pubitemid 32530848)
4. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-6. (Pubitemid 23172848)
5. Lanzi C, Perego IP Supino R, Romanelli S, Pensa T Carenini N, et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998; 55: 1247-54. (Pubitemid 28206714)
6. Perego P Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999; 55: 528-34. (Pubitemid 29128110)
7. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20.
8. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988; 27: 4730-4.
9. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-90.
10. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996; 56: 1374-81.
11. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90. (Pubitemid 26199755)
12. Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N, et al. Role of apoptosis and apoptosis-related proteins in the cisp-latin-resistant phenotype of human tumor cell lines. Apoptosis 1997; 2: 540-8. (Pubitemid 127507984)
13. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997; 9: 79-87. (Pubitemid 27142557)
14. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, et al. Monitoring the expression profiles of doxor-ubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000; 60: 4161-6. (Pubitemid 30636599)
15. Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, et al. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 2000; 83: 1047-54.
16. Johnsson A, Byrne P, de Bruin R, Weiner D, Wong J, Los G. Identification of gene clusters differentially expressed during the cellular injury responses (CIR) to cisplatin. Br J Cancer 2001; 85: 1206-10. (Pubitemid 33052322)
17. Black MM, Speer FD. Effects of cancer chemotherapeutic agents on dehydrogenase activity of human cancer tissue in vitro. Am J Clin Pathol 1953; 23: 218-27.
18. Black MM, Speer FD. Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue. J Natl Cancer Inst 1954; 14: 1147-58.
19. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33. (Pubitemid 10138923)
20. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34: 1493-9. (Pubitemid 28446328)
21. Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004; 92: 160-6. (Pubitemid 38147385)
22. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999; 154: 981-6. (Pubitemid 29169731)
23. Wang Y, Rea T Bian J, Gray S, Sun Y. Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology. FEBS Lett 1999; 445: 269-73. (Pubitemid 29117225)
24. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo 2000; 14: 173-82. (Pubitemid 30189227)
25. Oh SJ, Cho SJ, Kim CO, Park JW Characteristics of DNA micro-arrays fabricated on the various aminosilane layers. Langmuir 2002; 18: 1764-9. (Pubitemid 35383985)
26. Gao JH, He ZJ, Wang Q, Li X, Li YX, Liu M, et al. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line. Chin Med J (Engl) 2008; 121: 1563-8.
27. Oh SJ, Ju J, Kim BC, Ko E, Hong BJ, Park JG, et al. DNA micro-arrays on a dendron-modified surface improve significantly the detection of single nucleotide variations in the p53 gene. Nucleic Acids Res 2005; 33: e90.
28. Yang YH, Dudoit S, Luu P Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30: e15.
29. Kelleher DJ, Gilmore R. DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. Proc Natl Acad Sci U S A 1997; 94: 4994-9. (Pubitemid 27214724)
30. Brewster JL, Martin SL, Toms J, Goss D, Wang K, Zachrone K, et al. Deletion of Dad1 in mice induces an apoptosis-associated embryonic death. Genesis 2000; 26: 271-8. (Pubitemid 30305389)
31. Tian Q, Taupin J, Elledge S, Robertson M, Anderson P. Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J Exp Med 1995; 182: 865-74.
32. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24: 45-8. (Pubitemid 30041418)